Madrigal Pharmaceuticals, Inc. (MDGL)
471.75
-5.16
(-1.08%)
USD |
NASDAQ |
Oct 09, 16:00
471.86
+0.11
(+0.02%)
After-Hours: 20:00
Madrigal Pharmaceuticals Cash from Operations (Quarterly) : 23.33M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.33M |
| March 31, 2026 | -167.44M |
| December 31, 2025 | -133.46M |
| September 30, 2025 | 79.85M |
| June 30, 2025 | -47.05M |
| March 31, 2025 | -88.89M |
| December 31, 2024 | -104.49M |
| September 30, 2024 | -66.98M |
| June 30, 2024 | -134.94M |
| March 31, 2024 | -149.16M |
| December 31, 2023 | -79.93M |
| September 30, 2023 | -84.92M |
| June 30, 2023 | -75.31M |
| March 31, 2023 | -84.07M |
| December 31, 2022 | -58.52M |
| September 30, 2022 | -59.07M |
| June 30, 2022 | -57.36M |
| March 31, 2022 | -49.91M |
| December 31, 2021 | -48.05M |
| September 30, 2021 | -45.56M |
| June 30, 2021 | -46.88M |
| March 31, 2021 | -43.43M |
| December 31, 2020 | -54.95M |
| September 30, 2020 | -47.85M |
| June 30, 2020 | -24.26M |
| Date | Value |
|---|---|
| March 31, 2020 | -30.51M |
| December 31, 2019 | -12.28M |
| September 30, 2019 | -11.32M |
| June 30, 2019 | -11.54M |
| March 31, 2019 | -6.478M |
| December 31, 2018 | -6.265M |
| September 30, 2018 | -5.238M |
| June 30, 2018 | -5.36M |
| March 31, 2018 | -8.644M |
| December 31, 2017 | -5.945M |
| September 30, 2017 | -4.951M |
| June 30, 2017 | -7.65M |
| March 31, 2017 | -3.771M |
| December 31, 2016 | -5.28M |
| September 30, 2016 | -9.243M |
| June 30, 2016 | -2.647M |
| March 31, 2016 | -0.438M |
| December 31, 2015 | -1.096M |
| September 30, 2015 | 34.46M |
| June 30, 2015 | -17.73M |
| March 31, 2015 | -18.78M |
| December 31, 2014 | -19.22M |
| September 30, 2014 | -18.57M |
| June 30, 2014 | -20.87M |
| March 31, 2014 | -20.27M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Insmed, Inc. | -88.83M |
| United Therapeutics Corp. | 310.20M |
| Karyopharm Therapeutics, Inc. | -24.93M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 34.20M |
| Cash from Financing (Quarterly) | 3.112M |
| Free Cash Flow | -209.28M |
| Free Cash Flow Per Share (Quarterly) | 0.6545 |
| Free Cash Flow to Equity (Quarterly) | 18.64M |
| Free Cash Flow to Firm (Quarterly) | 27.02M |
| Free Cash Flow Yield | -1.71% |